Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NeuroSense Therapeutics Ltd. Warrant (NRSNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NRSNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -81.58% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.6 | 52 Weeks Range 0.10 - 1.06 | Updated Date 06/21/2025 |
52 Weeks Range 0.10 - 1.06 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -159.5% | Return on Equity (TTM) -2478.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 11925007 |
Shares Outstanding - | Shares Floating 11925007 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NeuroSense Therapeutics Ltd. Warrant
Company Overview
History and Background
NeuroSense Therapeutics Ltd. is a biotechnology company focused on discovering and developing treatments for neurodegenerative diseases. The warrants give the holder the right to purchase common stock at a specified price and date.
Core Business Areas
- Drug Development: Research and development of therapeutics targeting neurodegenerative diseases like ALS and Alzheimer's. Their main focus is on developing small molecule drugs to treat these conditions.
Leadership and Structure
The leadership team consists of experienced professionals in drug development and biotechnology management. The organizational structure likely includes research, development, and clinical trial departments.
Top Products and Market Share
Key Offerings
- PrimeC: PrimeC is NeuroSense's leading drug candidate for ALS. Currently undergoing clinical trials. While specific market share data is unavailable due to its developmental stage, potential competitors include Mitsubishi Tanabe Pharma (Radicava) and Amylyx Pharmaceuticals (Relyvrio).
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing due to the aging global population. It is characterized by high unmet needs and intense competition.
Positioning
NeuroSense is a smaller player in a market dominated by larger pharmaceutical companies. They are focused on developing novel therapies.
Total Addressable Market (TAM)
The total addressable market for neurodegenerative disease treatments is estimated to be in the tens of billions of dollars. NeuroSense is positioning itself to capture a portion of this market with its pipeline of drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet needs
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on clinical trial success
- Single product focus
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new indications
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- AMTX
- ABBV
- BMY
Competitive Landscape
NeuroSense is a small biotech company competing with larger, more established pharmaceutical companies. Their advantage lies in their novel drug candidates and focus on specific neurodegenerative diseases. The main disadvantages are the reliance on clinical trial success and fund-raising.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to preclinical and clinical development milestones rather than revenue growth.
Future Projections: Future growth is dependent on the successful development and commercialization of PrimeC and other drug candidates.
Recent Initiatives: Recent initiatives include advancing PrimeC through clinical trials and exploring new indications.
Summary
NeuroSense Therapeutics is a clinical-stage biotech firm focused on neurodegenerative disease treatments, primarily PrimeC for ALS. Its strength lies in novel drug development, but it faces weaknesses like limited resources and reliance on clinical trial outcomes. Opportunities exist in partnerships and new indications. Investors should watch out for clinical trial results and funding challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be entirely accurate or complete. Investing in warrants, particularly in early-stage biotech companies, carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NeuroSense Therapeutics Ltd. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-12-09 | Co-Founder, CEO & Director Mr. Alon Ben-Noon | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.neurosense-tx.com |
Full time employees 17 | Website https://www.neurosense-tx.com | ||
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.